Table 2 . Study variables in Mg treated and placebo group after 3 months intervention.
MgSO 4 group (n =25) | Placebo group (n = 22) | ||
End | End | p | |
Age (years) | ________ | ________ | ________ |
Sex (male/female) | ________ | ________ | ________ |
Duration of diabetes (years) | ________ | ________ | ________ |
BMI (kg/m2) | 26.41 ± 3.29 | 27.28 ± 5.13 | Not significant |
Systolic blood pressure ( mm Hg) | 102.8 ± 9.51 | 117.2 ± 3.48 | <0.001 |
Diastolic blood pressure ( mm Hg) | 62.85 ± 7.55 | 70 ± 7.07 | <0.05 |
Serum Mg (mg/dl) | 2.16 ± 0.36 | 2.23 ± 0.50 | Not significant |
Urine Mg (mg/dl) | 5.99 ± 2 | 4.56 ± 1.72 | <0.05 |
Calcium to magnesium ratio | 4.64 ± 1.46 | 5.21 ± 1.65 | Not significant |
Fasting blood glucose (mg/dl) | 125.8 ± 6.52 | 136.5 ± 7.94 | <0.0001 |
2hr PP blood glucose (mg/dl) | 189.1 ± 60.05 | 247.8 ± 86.74 | <0.01 |
HbA1C (%) | 7.90 ± 1.68 | 7.61 ± 1.59 | Not significant |
HOMA-IR index | 5.01 ± 2.47 | 4.65 ± 3.48 | Not significant |
Fasting plasma insulin (qIU/ml) | 15.90 ± 8.02 | 13.35 ± 11.53 | Not significant |
Triglycerides (mg/dl) | 158.7 ± 77.16 | 175.5 ± 107.5 | Not significant |
Total cholesterol (mg/dl) | 176.2 ± 48.33 | 182.7 ± 56.23 | Not significant |
LDL cholesterol (mg/dl) | 93.63 ± 24.58 | 120.4 ± 34.86 | <0.01 |
HDL cholesterol (mg/dl) | 41.7 ± 8.79 | 43.65 ± 11.20 | Not significant |
Non HDL cholesterol (mg/dl) | 125.30 ± 23.19 | 152.16 ± 37.05 | <0.001 |
Hemoglobin concentration (gr/dl) | 13.46 ± 1.51 | 13.18 ± 1.71 | Not significant |
Aspartate transfrase (IU/ml) | 18.15 ± 10.40 | 24.92 ± 12.12 | Not significant |
Alanin transfrase (IU/ml) | 22.30 ± 2.83 | 33.93 ± 5.70 | <0.05 |
Metformin dosage ( mg ) | 1371.42 ± 625.21 | 1750 ± 379.77 | <0.01 |
Glibenclamid dosage ( mg ) | 10.76 ± 7.10 | 13.31 ± 6.18 | Not significant |
Enalapril dosage (mg) | 13 ± 4.6 | 23 ± 6.6 | <0.01 |
Atorvastatin dosage (mg) | 15 ± 1.88 | 17.5 ± 3.65 | Not significant |
Data are means ± SD.